Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence